Table I.
Associations between CMTM3 expression and clinicopathological features of 110 ESCC patients.
| CMTM3 expression | ||||
|---|---|---|---|---|
| Clinicopathological parameters | Patients, n | Low | High | P-value |
| Age, years | 0.280 | |||
| ≤60 | 48 | 37 | 11 | |
| >60 | 62 | 42 | 20 | |
| Gender | 0.275 | |||
| Male | 97 | 68 | 29 | |
| Female | 13 | 11 | 2 | |
| Location | 0.357 | |||
| Ut | 26 | 19 | 7 | |
| Mt | 32 | 20 | 12 | |
| Lt | 52 | 40 | 12 | |
| Pathological grade | 0.730 | |||
| Moderately/poorly-differentiated | 61 | 43 | 18 | |
| Well-differentiated | 49 | 36 | 13 | |
| Lymph node metastasis | 0.002 | |||
| Negative | 56 | 33 | 23 | |
| Positive | 54 | 46 | 8 | |
| Clinical stage | 0.001 | |||
| I+II | 58 | 33 | 25 | |
| III+IV | 52 | 46 | 6 | |
CMTM3, human chemokine-like factor-like MARVEL transmembrane domain-containing 3; ESCC, esophageal squamous cell carcinoma; Ut, upper thoracic; Mt, middle thoracic; Lt, lower thoracic.